CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia

CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia

Abstract Background Leukemia stem cells (LSCs) are responsible for the initiation, progression, and relapse of acute myeloid leukemia (AML). Therefore, a therapeutic strategy targeting LSCs is a potential approach to eradicate AML. In this study, we aimed to identify LSC-specific surface markers and...

Full description

Bibliographic Details
Main Authors: Yongliang Liu, Guiqin Wang, Jiasi Zhang, Xue Chen, Huailong Xu, Gang Heng, Jun Chen, Yongchun Zhao, Jiatao Li, Yuanli Ni, Yingzi Zhang, Juanjuan Shan, Cheng Qian
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Stem Cell Research & Therapy
Subjects:
Acute myeloid leukemia (AML)
Leukemia stem cells (LSCs)
CD9
Alpha-2-macroglobulin (A2M)
Biomarker
Online Access:https://doi.org/10.1186/s13287-021-02155-6

Internet

https://doi.org/10.1186/s13287-021-02155-6

Similar Items